However, several professional societies and regulatory bodies have recommended continuing standard therapy using ACE inhibitor and ARB.
Hata hivyo, mashirika mengi ya kitaalamu na ya usimamizi yamependekeza kuendelea na kizuzi cha kawaida cha ACE na matibabu ya ARB.